blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1603575

EP1603575 - NEMORUBICIN AS RADIOSENSITIZER IN COMBINATION WITH RADIATION THERAPY AGAINST TUMORS [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  13.10.2006
Database last updated on 03.10.2024
Most recent event   Tooltip13.10.2006Application deemed to be withdrawnpublished on 15.11.2006  [2006/46]
Applicant(s)For all designated states
Pharmacia Italia S.p.A.
Via Robert Koch, 1.2
20152 Milano / IT
[2005/50]
Inventor(s)01 / GERONI, Maria, Cristina, Rosa
Via Correggio, 48
I-20149 Milan / IT
02 / PACCIARINI, Maria, Adele
Via Degli Imbriani, 39
I-20158 Milan / IT
03 / SUARATO, Antonino
Via Degli Imbriani, 39
I-MILAN 20158 / IT
 [2005/50]
Representative(s)Modiano, Micaela Nadia, et al
Modiano Josif Pisanty & Staub Ltd
Thierschstrasse 11
80538 München / DE
[N/P]
Former [2005/50]Modiano, Micaela Nadia, et al
Modiano, Josif, Pisanty & Staub Ltd., Baaderstrasse 3
80469 München / DE
Application number, filing date04716607.903.03.2004
[2005/50]
WO2004EP50246
Priority number, dateEP2003007578118.03.2003         Original published format: EP 03075781
[2005/50]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2004082579
Date:30.09.2004
Language:EN
[2004/40]
Type: A2 Application without search report 
No.:EP1603575
Date:14.12.2005
Language:EN
The application published by WIPO in one of the EPO official languages on 30.09.2004 takes the place of the publication of the European patent application.
[2005/50]
Search report(s)International search report - published on:EP11.11.2004
ClassificationIPC:A61K31/704, A61P35/00, A61K31/282
[2005/50]
CPC:
A61K45/06 (EP); A61K33/243 (EP,US); A61K31/282 (EP);
A61K31/704 (EP); A61K41/00 (EP); A61P35/00 (EP)
C-Set:
A61K31/282, A61K2300/00 (EP);
A61K31/704, A61K2300/00 (EP);
A61K33/24, A61K2300/00 (EP);
A61K41/00, A61K2300/00 (EP)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IT,   LI,   LU,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2005/50]
Extension statesALNot yet paid
LTNot yet paid
LVNot yet paid
MKNot yet paid
TitleGerman:NEMORUBICIN ALS STRAHLUNGSSENSIBILISATOR ZUSAMMEN MIT STRAHLENTHERAPIE GEGEN KREBS[2005/50]
English:NEMORUBICIN AS RADIOSENSITIZER IN COMBINATION WITH RADIATION THERAPY AGAINST TUMORS[2005/50]
French:POLYTHERAPIE CONTRE DES TUMEURS COMPRENANT L'ADMINISTRATION DE NEMORUBICINE COMBINEE A UNE RADIOTHERAPIE[2005/50]
Entry into regional phase19.09.2005National basic fee paid 
19.09.2005Designation fee(s) paid 
19.09.2005Examination fee paid 
Examination procedure08.10.2004Request for preliminary examination filed
International Preliminary Examining Authority: EP
19.09.2005Amendment by applicant (claims and/or description)
19.09.2005Examination requested  [2005/50]
17.01.2006Despatch of a communication from the examining division (Time limit: M04)
29.05.2006Application deemed to be withdrawn, date of legal effect  [2006/46]
30.06.2006Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time  [2006/46]
Fees paidRenewal fee
06.03.2006Renewal fee patent year 03
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[XD]US4672057  (BARGIOTTI ALBERTO [IT], et al) [XD] 1-15 * the whole document *;
 [XD]US4710564  (OTAKE NOBORU [JP], et al) [XD] 1-15 * the whole document *;
 [XD]GB2296495  (ERBA CARLO SPA [IT], et al) [XD] 1-15 * the whole document *;
 [XD]GB2315067  (PHARMACIA SPA [IT], et al) [XD] 1-15 * the whole document *;
 [XP]WO03082267  (PHARMACIA ITALIA SPA [IT], et al) [XP] 1-15 * page 1, paragraph 1 * * page 4, paragraph 3 - page 4, line 21 *;
 [X]  - The combination of nemorubicin with cisplatin and mitomycin C is synergistic in experimental tumor models, EUROPEAN JOURNAL OF CANCER, PERGAMON PRESS, OXFORD, GB, PAGE(S) S20, (200211), ISSN 0959-8049, XP004403486 [X] 1-18 * abstract *
 [X]  - KABUTO M ET AL, [Antitumor effect of MX2, a new morpholino anthracycline against C6 glioma cells and its combination effect with photodynamic therapy in vitro], NO TO SHINKEI. BRAIN AND NERVE. OCT 1995, VOL. 47, NR. 10, PAGE(S) 969 - 973, (199510), ISSN 0006-8969, XP009033767 [X] 1-3,6-15 * abstract *
 [X]  - "Preclinical activity against liver metastases of Nemorubicin, a DNA-intercalating cytotoxic agent for the treatment of hepatocellular carcinoma", EUROPEAN JOURNAL OF CANCER, PERGAMON PRESS, OXFORD, GB, (200211), vol. 38, ISSN 0959-8049, page S19, XP004403483 [X] 1-14 * abstract *
 [X]  - "Properties of the new anthracycline derivative containing modified daunosamine moiety", EUROPEAN JOURNAL OF CANCER, PERGAMON PRESS, OXFORD, GB, (200211), vol. 38, ISSN 0959-8049, pages S19 - S20, XP004403485 [X] 1-15 * abstract *
 [Y]  - BONNER J A ET AL, Doxorubicin decreases the repair of radiation-induced DNA damage, INTERNATIONAL JOURNAL OF RADIATION BIOLOGY 1990 UNITED KINGDOM, VOL. 57, NR. 1, PAGE(S) 55-64, (1990), ISSN 0020-7616, XP009033771 [Y] 1-15 * abstract *
 [Y]  - BONNER J A ET AL, "DOXORUBICIN ENHANCES RADIATION-INDUCED DNA DAMAGE", INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY, BIOLOGY, PHYSICS, & 30TH ANNUAL MEETING OF THE AMERICAN SOCIETY FOR THERAPEUTIC RADIOLOGY AND ONCOLOGY, NEW ORLEANS, LOU, (1988), vol. 15, no. SUPPL. 1, ISSN 0360-3016, page 163, XP009033770 [Y] 1-15 * abstract *
 [Y]  - WU LI-TEH, "Doxorubicin as radiation potentiator: Concurrent doxorubicin and radiation therapy interaction and its clinical applications", INFUSION CHEMOTHERAPY: IRRADIATION INTERACTIONS: PRINCIPLES AND APPLICATIONS TO ORGAN SALVAGE AND PREVENTION OF SECOND PRIMARY NEOPLASMS ELSEVIER SCIENCE PUBLISHERS B.V., PO BOX 211, SARA BURGERHARTSTRAAT 25, 1000 AE AMSTERDAM, THE NETHERLANDS; ELSEV, (1998), ISSN 0-444-82608-4, pages 147 - 151, XP002289046 [Y] 1-15 * the whole document *
 [Y]  - JAGETIA GANESH CHANDRA ET AL, "Effect of doxorubicin on cell survival and micronuclei formation in HeLa cells exposed to different doses of gamma-radiation", STRAHLENTHERAPIE UND ONKOLOGIE, (200009), vol. 176, no. 9, ISSN 0179-7158, pages 422 - 428, XP002289047 [Y] 1-15 * abstract *
 [Y]  - CHENOUFI NORCHEN ET AL, "In vitro demonstration of synergy between radionuclide and chemotherapy", JOURNAL OF NUCLEAR MEDICINE, (199805), vol. 39, no. 5, ISSN 0161-5505, pages 900 - 903, XP009033769 [Y] 1-15 * abstract *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.